These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31899530)

  • 1. Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression.
    Zhdanov A; Atluri S; Wong W; Vaghei Y; Daskalakis ZJ; Blumberger DM; Frey BN; Giacobbe P; Lam RW; Milev R; Mueller DJ; Turecki G; Parikh SV; Rotzinger S; Soares CN; Brenner CA; Vila-Rodriguez F; McAndrews MP; Kleffner K; Alonso-Prieto E; Arnott SR; Foster JA; Strother SC; Uher R; Kennedy SH; Farzan F
    JAMA Netw Open; 2020 Jan; 3(1):e1918377. PubMed ID: 31899530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
    Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
    J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
    Uher R; Tansey KE; Dew T; Maier W; Mors O; Hauser J; Dernovsek MZ; Henigsberg N; Souery D; Farmer A; McGuffin P
    Am J Psychiatry; 2014 Dec; 171(12):1278-86. PubMed ID: 25017001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
    Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
    Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
    Uher R; Frey BN; Quilty LC; Rotzinger S; Blier P; Foster JA; Müller DJ; Ravindran AV; Soares CN; Turecki G; Parikh SV; Milev R; MacQueen G; Lam RW; Kennedy SH;
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of machine learning in predicting clinical response to transcranial magnetic stimulation in comorbid posttraumatic stress disorder and major depression: A resting state electroencephalography study.
    Zandvakili A; Philip NS; Jones SR; Tyrka AR; Greenberg BD; Carpenter LL
    J Affect Disord; 2019 Jun; 252():47-54. PubMed ID: 30978624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
    Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
    JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
    Uher R; Mors O; Rietschel M; Rajewska-Rager A; Petrovic A; Zobel A; Henigsberg N; Mendlewicz J; Aitchison KJ; Farmer A; McGuffin P
    J Clin Psychiatry; 2011 Nov; 72(11):1478-84. PubMed ID: 22127194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
    Moore N; Verdoux H; Fantino B
    Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.